The data from the abstract of the study at ASCO shows that Keytruda plus chemo improved progression-free survival (PFS) to 9.7 months, compared to 5.6 months for chemo alone, which was a ...

Drug discovery firm Exscientia has claimed a world first after announcing that the first precision engineered drug generated by artificial intelligence (AI) is entering clinical trials. UK-based ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...